NPV-LDE-225 (Erismodegib) inhibits epithelial mesenchymal transition and self-renewal of glioblastoma initiating cells by regulating miR-21, miR-128, and miR-200

Neuro-Oncology

Volumn 15, Issue 6, 2013, Pages 691-706

  Fu, Junsheng ^a   Rodova, Mariana ^a   Nanta, Rajesh ^a   Meeker, Daniel ^a   Van Veldhuizen, Peter J ^b   Srivastava, Rakesh K ^a   Shankar, Sharmila ^a  

^a UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

brain cancer stem cells; cell survival; Gli transcription factors; glioblastoma initiating cells; NPV LDE 225; sonic hedgehog signaling

Indexed keywords

BMI1 PROTEIN; CASPASE 3; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FAS ANTIGEN; FAS LIGAND; MICRORNA; MICRORNA 128; MICRORNA 200; MICRORNA 21; MYC PROTEIN; NERVE CELL ADHESION MOLECULE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OCTAMER TRANSCRIPTION FACTOR 4; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN BCL 2; SHORT HAIRPIN RNA; SONIDEGIB; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR GLI2; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTION FACTOR ZEB1; UNCLASSIFIED DRUG; UVOMORULIN;

APOPTOSIS; ARTICLE; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL RENEWAL; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLIOBLASTOMA; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR CELL; UPREGULATION;

BRAIN CANCER STEM CELLS; CELL SURVIVAL; GLI TRANSCRIPTION FACTORS; GLIOBLASTOMA INITIATING CELLS; NPV-LDE-225; SONIC HEDGEHOG SIGNALING;

APOPTOSIS; BIPHENYL COMPOUNDS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CADHERINS; CASPASE 3; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; EPITHELIAL-MESENCHYMAL TRANSITION; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HEDGEHOG PROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; MICRORNAS; NEOPLASTIC STEM CELLS; POLYCOMB REPRESSIVE COMPLEX 1; PYRIDINES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 84878343722     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not011     Document Type: Article

References (62)

1. Haldipur P, Bharti U, Govindan S, et al. Expression of sonic hedgehog during cell proliferation in the human cerebellum. Stem Cells Dev. 2012; 21(7): 1059-1068.
2. Bar EE, Chaudhry A, Lin A, et al. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells. 2007; 25(10): 2524-2533.
3. Ehtesham M, Sarangi A, Valadez JG, et al. Ligand-dependent activation of the hedgehog pathway in glioma progenitor cells. Oncogene. 2007; 26(39): 5752-5761.
4. Wakimoto H, Mohapatra G, Kanai R, et al. Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells. Neuro Oncol. 2012; 14(2): 132-144.
5. Xu Q, Yuan X, Liu G, Black KL, Yu JS. Hedgehog signaling regulates brain tumor-initiating cell proliferation and portends shorter survival for patients with PTEN-coexpressing glioblastomas. Stem Cells. 2008; 26(12): 3018-3026.
6. Michael LE, Westerman BA, Ermilov AN, et al. Bmi1 is required for hedgehog pathway-driven medulloblastoma expansion. Neoplasia. 2008; 10(12): 1343-1349. 1345p following 1349.
7. Yung SY, Gokhan S, Jurcsak J, Molero AE, Abrajano JJ, Mehler MF. Differential modulation of BMP signaling promotes the elaboration of cerebral cortical GABAergic neurons or oligodendrocytes from a common sonic hedgehog-responsive ventral forebrain progenitor species. Proc Nat Acad Sci U S A. 2002; 99(25): 16273-16278.
8. Hatten ME, Roussel MF. Development and cancer of the cerebellum. Trends Neurosci. 2011; 34(3): 134-142.
9. Ulasov IV, Nandi S, DeyM, Sonabend AM, LesniakMS. Inhibition of sonic hedgehog and Notch pathways enhances sensitivity of CD133(+) glioma stem cells to temozolomide therapy. Mol Med. 2011; 17(1-2): 103-112.
10. Yoshimoto K, Ma X, Guan Y, et al. Expression of stem cell marker and receptor kinase genes in glioblastoma tissue quantified by real-time RT-PCR. Brain Tumor Pathol. 2011; 28(4): 291-296.
11. Buonamici S, Williams J, Morrissey M, et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med. 2010; 2(51): 51ra70.
12. Cloninger C, Bernath A, Bashir T, et al. Inhibition of SAPK2/p38 enhances sensitivity to mTORC1 inhibition by blocking IRES-mediated translation initiation in glioblastoma. Mol Cancer Ther. 2011; 10(12): 2244-2256.
13. Xie J. Hedgehog signaling pathway: development of antagonists for cancer therapy. Curr Oncol Rep. 2008; 10(2): 107-113.
14. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005; 353(19): 2012-2024.
15. Fan QW, Knight ZA, Goldenberg DD, et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell. 2006; 9(5): 341-349.
16. Jackson EL, Garcia-Verdugo JM, Gil-Perotin S, et al. PDGFR alphapositive B cells are neural stem cells in the adult SVZ that form gliomalike growths in response to increased PDGF signaling. Neuron. 2006; 51(2): 187-199.
17. Ligon KL, Huillard E, Mehta S, et al. Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron. 2007; 53(4): 503-517.
18. Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruiz i Altaba A. Hedgehog-Gli1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol. 2007; 17(2): 165-172.
19. Mazzola CA, Pollack IF. Medulloblastoma. Curr Treat Options Neurol. 2003; 5(3): 189-198.
20. Tanori M, Santone M, Mancuso M, et al. Developmental and oncogenic effects of insulin-like growth factor-I in Ptc1+/- mouse cerebellum. Mol Cancer. 2010; 9: 53.
21. Traiffort E, Angot E, Ruat M. Sonic hedgehog signaling in the mammalian brain. J Neurochem. 2010; 113(3): 576-590.
22. Alberta JA, Park SK, Mora J, et al. Sonic hedgehog is required during an early phase of oligodendrocyte development in mammalian brain. Mol Cell Neurosci. 2001; 18(4): 434-441.
23. Matise MP, Wang H. Sonic hedgehog signaling in the developing CNS: where it has been and where it is going. Curr Top Dev Biol. 2011; 97: 75-117.
24. Pepicelli CV, Lewis PM, McMahon AP. Sonic hedgehog regulates branching morphogenesis in the mammalian lung. Curr Biol. 1998; 8(19): 1083-1086.
25. Ruiz i Altaba A, Sanchez P, Dahmane N. Gli and hedgehog in cancer: tumours, embryos and stem cells. Nat Rev Cancer. 2002; 2(5): 361-372.
26. Taylor MD, Liu L, Raffel C, et al. Mutations in Sufu predispose to medulloblastoma. Nat Genet. 2002; 31(3): 306-310.
27. Thomas WD, Chen J, Gao YR, et al. Patched1 deletion increases N-Myc protein stability as a mechanism of medulloblastoma initiation and progression. Oncogene. 2009; 28(13): 1605-1615.
28. Hallahan AR, Pritchard JI, Hansen S, et al. The SmoA1 mouse model reveals that Notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res. 2004; 64(21): 7794-7800.
29. Christensen K, Schroder HD, Kristensen BW. CD133+ niches and single cells in glioblastoma have different phenotypes. J Neurooncol. 2011; 104(1): 129-143.
30. Basset-Seguin N, Soufir N. [Patched/sonic hedgehog pathway and basal cell carcinoma]. Med Sci (Paris). 2004; 20(10): 899-903.
31. Ruiz i Altaba A, Palma V, Dahmane N. Hedgehog-Gli signalling and the growth of the brain. Nat Rev Neurosci. 2002; 3(1): 24-33.
32. Singh BN, Fu J, Srivastava RK, Shankar S. Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms. PLoS One. 2011; 6(11): e27306.
33. Skvara H, Kalthoff F, Meingassner JG, et al. Topical treatment of basal cell carcinomas in nevoid basal cell carcinoma syndrome with a smoothened inhibitor. J Invest Dermatol. 2011; 131(8): 1735-1744.
34. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009; 139(5): 871-890.
35. Gunasinghe NP, Wells A, Thompson EW, Hugo HJ. Mesenchymalepithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer. Cancer Metastasis Rev. 2013; 31(3-4): 469-478.
36. Yoo YA, Kang MH, Lee HJ, et al. Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in gastric cancer. Cancer Res. 2011; 71(22): 7061-7070.
37. Huber MA, Kraut N, Beug H. Molecular requirements for epithelialmesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005; 17(5): 548-558.
38. Kloosterman WP, Plasterk RH. The diverse functions of microRNAs in animal development and disease. Dev Cell. 2006; 11(4): 441-450.
39. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006; 6(4): 259-269.
40. Ciafre SA, Galardi S, Mangiola A, et al. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun. 2005; 334(4): 1351-1358.
41. Bruggeman SW, Hulsman D, Tanger E, et al. Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. Cancer Cell. 2007; 12(4): 328-341.
42. Valk-Lingbeek MEBS, van Lohuizen M. Stem cells and cancer: the polycomb connection. Cell. 2004; 118: 409-418.
43. Bracken AP DN, Pasini D, Hansen KH, Helin K. Genome-wide mapping of polycomb target genes unravels their roles in cell fate transitions. Genes Dev. 2006; 20: 1123-1136.
44. Fasano CA, Dimos JT, Ivanova NB, Lowry N, Lemischka IR, Temple S. ShRNA knockdown of Bmi-1 reveals a critical role for p21-Rb pathway in NSC self-renewal during development. Cell Stem Cell. 2007; 1(1): 87-99.
45. Zencak D, Lingbeek M, Kostic C, et al. Bmi1 loss produces an increase in astroglial cells and a decrease in neural stem cell population and proliferation. J Neurosci. 2005; 25(24): 5774-5783.
46. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer. 2006; 6(11): 846-856.
47. Godlewski J, Nowicki MO, Bronisz A, et al. Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res. 2008; 68(22): 9125-9130.
48. Leung C, Lingbeek M, Shakhova O, et al. Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature. 2004; 428(6980): 337-341.
49. Abdouh M, Facchino S, Chatoo W, Balasingam V, Ferreira J, Bernier G. Bmi1 sustains human glioblastoma multiforme stem cell renewal. J Neurosci. 2009; 29(28): 8884-8896.
50. Gaur AB, Holbeck SL, Colburn NH, Israel MA. Downregulation of PDCD4 by miR-21 facilitates glioblastoma proliferation in vivo. Neuro Oncol. 2011; 13(6): 580-590.
51. Guo L, Fan L, Pang Z, et al. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes. J Control Release. 2011; 154(1): 93-102.
52. Kuijlen JM, Bremer E, Mooij JJ, den DunnenWF, Helfrich W. Review: on TRAIL for malignant glioma therapy? Neuropathol Appl Neurobiol. 2010; 36(3): 168-182.
53. Yin D, Zhou H, Kumagai T, et al. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene. 2005; 24(3): 344-354.
54. Avril T, Saikali S, Vauleon E, et al. Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions. J Neuroimmunol. 2010; 225(1-2): 22-33.
55. Choi K, Benveniste EN, Choi C. Induction of intercellular adhesion molecule- 1 by Fas ligation: proinflammatory roles of Fas in human astroglioma cells. Neurosci Letters. 2003; 352(1): 21-24.
56. Iwatsuki M, Mimori K, Yokobori T, et al. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 2010; 101(2): 293-299.
57. Monteiro J, Fodde R. Cancer stemness and metastasis: therapeutic consequences and perspectives. Eur J Cancer. 2010; 46(7): 1198-1203.
58. Vescovi AL, Galli R, Reynolds BA. Brain tumour stem cells. Nat Rev Cancer. 2006; 6(6): 425-436.
59. Leary SE, Olson JM. The molecular classification of medulloblastoma: driving the next generation clinical trials. Curr Opin Pediatr. 2012; 24(1): 33-39.
60. Bourdeaut F, Miquel C, Alapetite C, Roujeau T, Doz F. Medulloblastomas: update on a heterogeneous disease. Curr Opin Oncol. 2011; 23(6): 630-637.
61. Swartling FJ. Myc proteins in brain tumor development and maintenance. Upsala J Med Sci. 2012; 117(2): 122-131.
62. Wang J, Wang H, Li Z, et al. c-Myc is required for maintenance of glioma cancer stem cells. PLoS One. 2008; 3(11): e3769.